EVGN
Evogene Ltd.
There isn't enough reported data to score EVGN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
EVGN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
EVGN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EVGN PE Valuation
EVGN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EVGN Forward outlook
There aren't enough analyst estimates for EVGN to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EVGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.91 | +$1.34 |
| Q1 2026 | -$1.39 | +$1.30 |
| Q4 2025 | -$1.17 | +$1.90 |
| Q3 2025 | -$0.50 | +$3.93 |
| Q2 2025 | -$2.25 | +$1.68 |
| Q1 2025 | -$2.69 | +$1.73 |
| Q4 2024 | -$3.07 | +$2.10 |
EVGN is still losing money, but far less than before: $0.91 per share over the past year, against $5.17 at its worst in late 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EVGN on earnings quality, reporting a profit while its opponent remains loss making.
EVGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $347K | -61% |
| Q1 2026 | $334K | -86% |
| Q4 2025 | $314K | -81% |
| Q3 2025 | $312K | -82% |
| Q2 2025 | $884K | +46% |
| Q1 2025 | $2.4M | -42% |
| Q4 2024 | $1.6M | +179% |
| Q3 2024 | $1.7M | -54% |
EVGN's revenue has slid since its 2024 peak: $347,000 last quarter, down 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -703% | -356 points |
| Q1 2026 | -943% | -774 points |
| Q4 2025 | -1660% | -1376 points |
| Q3 2025 | -873% | -533 points |
| Q2 2025 | -347% | +418 points |
| Q1 2025 | -169% | -71 points |
| Q4 2024 | -283% | +1036 points |
| Q3 2024 | -340% | -229 points |
EVGN's operating margin was −703% last quarter, down 356 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EVGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EVGN on profitability, with a higher operating margin.
EVGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.1M | +$224K |
| Q1 2026 | -$3M | +$2.3M |
| Q4 2025 | -$2.7M | +$2.8M |
| Q3 2025 | -$3.8M | +$1.3M |
| Q2 2025 | -$2.3M | +$3.1M |
| Q1 2025 | -$5.3M | -$1.1M |
| Q4 2024 | -$5.5M | +$482K |
| Q3 2024 | -$5.1M | -$527K |
EVGN has burned cash in almost every quarter: −$12M over the past year, against −$18M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over EVGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
EVGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +2.5M shares |
| 1 year | +69% | +5M shares |
| 3 years | +170% | +7.7M shares |
EVGN has 12M diluted shares, up 69% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
EVGN hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EVGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EVGN Net Leverage
EVGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EVGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 10.1 | Oversold |
EVGN's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EVGN PE vs Healthcare Sector
EVGN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EVGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.37 | 2.7% below |
| 20 week MA | $0.47 | 23% below |
| 50 week MA | $0.70 | 49% below |
| 100 week MA | $1.00 | 64% below |
| 200 week MA | $3.71 | 90% below |
EVGN is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EVGN on trend strength, trading above more of its moving averages.
EVGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.6 | $44.1 | +183% |
| 2021 | $44.1 | $17.1 | -61% |
| 2022 | $17.1 | $7.59 | -56% |
| 2023 | $7.59 | $8.40 | +11% |
| 2024 | $8.40 | $1.65 | -80% |
| 2025 | $1.65 | $1.03 | -38% |
| 2026 YTD | $1.03 | $0.36 | -65% |
EVGN's yearly returns have swung widely, from +183% in 2020 to −80% in 2024. It's down 65% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EVGN on returns for 2026, with the stronger performance.